2015-05-05
Kancera provides operational update on the cancer projects
Kancera reports results from the company's cancer project portfolio generated in 2015.
Read More
2015-02-20
Full Year Report for Kancera AB (publ) Q4 2014 January 1 – December 31, 2014
In 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read More
2015-02-03
Kancera provides operational update on the ROR project
Kancera reports that a second efficacy study of the drug candidate KAN0439834 (small molecule inhibitor of ROR1) has been completed in an animal model of an advanced stage of chronic lymphocytic leukemia. The results show that KAN0439834 reduces the...
Read More
2014-12-10
Kancera provides operational update on the HDAC6 project
Kancera reports that an investigation of the mechanism of action of the company's patent-pending HDAC6 inhibitors has demonstrated a unique profile that could strengthen the competitiveness of the project.
Read More
2014-11-21
Interim Report for Kancera AB (publ) Q3 2014
January 1 - September 30, 2014. All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read More
2014-11-03
Kancera selects a first candidate drug in the ROR project
Kancera reports the results of an analysis of the preclinical efficacy study that was completed during the third quarter as reported in a press release on October 3, 2014. The results confirm that the number of cancer cells in...
Read More
2014-10-03
Kancera provides operational update on the ROR project
Kancera reports that an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) has been completed in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after...
Read More
2014-09-17
Kancera provides new information on the ROR project in connection with the “U.S. Cancer Immunotherapy Partnering Mission”
In connection with presentations for pharmaceutical companies and universities during the "U.S. Cancer Immunotherapy Partnering Mission" (CIPM), 15 -19 September 2014, Kancera communicates new information regarding the company's ROR1-directed small molecules and vaccine candidates. This information concerns the efficacy...
Read More
2014-08-22
Interim Report for Kancera AB (publ) Q2 2014
January 1 - June 30, 2014 All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. In connection with this Kancera...
Read More
2014-05-23
Interim Report for Kancera AB (publ) Q1 2014
All figures from the first quarter 2013 relate only to Kancera AB as a consequence of the liquidation of the subsidiary iNovacia AB in the beginning of 2013. Therefore there are no consolidated accounts for the Kancera Group produced...
Read More